A randomized, double-blind, placebo-controlled investigation of BCc1 nanomedicine effect on survival and quality of life in metastatic and non-metastatic gastric cancer patients

A randomized, double-blind, placebo-controlled investigation of BCc1 nanomedicine effect on survival and quality of life in metastatic and non-metastatic gastric cancer patients

Abstract Background Currently, the main goal of cancer research is to increase longevity of patients suffering malignant cancers. The promising results of BCc1 in vitro and vivo experiments made us look into the effect of BCc1 nanomedicine on patients with cancer in a clinical trial. Methods The pre...

Full description

Bibliographic Details
Main Authors: Maryam Hafizi, Somayeh Kalanaky, Hassan moaiery, Maryam Khayamzadeh, Sajad Noorian, Vahid Kaveh, Behrooz Gharib, Hossein Foudazi, Mohsen Razavi, Arash Jenabian, Saeid Salimi, Mohammad Mahdi Adib Sereshki, Hamid Reza Mirzaei, Afshin Zarghi, Saideh Fakharzadeh, Mohammad Hassan Nazaran, Mohammad Esmaeil Akbari
Format: Article
Language:English
Published: BMC 2019-04-01
Series:Journal of Nanobiotechnology
Subjects:
BCc1 nanomedicine
Cancer
Gastric cancer
Clinical trial
Nanomedicine
Nanochelating technology
Online Access:http://link.springer.com/article/10.1186/s12951-019-0484-0

Internet

http://link.springer.com/article/10.1186/s12951-019-0484-0

Similar Items